Global Viral Hepatitis Market Expected to Achieve 4.1% CAGR by 2029: Growth Forecast Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Viral Hepatitis Market Size By 2025?
The valuation of the viral hepatitis market has experienced consistent expansion across recent years, projected to advance from a value of $16.21 billion in 2024 to $16.77 billion in the subsequent year, reflecting a compound annual growth rate calculation of 3.4%; this upward trajectory witnessed during the historical span is primarily linked to advancements in vaccine creation, widespread implementation of blood testing protocols, the availability of antiviral medications, and various international public health campaigns.

How Big Is the Viral Hepatitis Market Size Expected to Grow by 2029?
Anticipating a consistent upward trajectory, the market encompassing viral hepatitis is projected to expand, reaching a valuation of $19.71 billion by the year 2029, driven by a compound annual growth rate (CAGR) of 4.1% throughout the forecast timeline; this expansion is fundamentally supported by augmented accessibility to therapeutic interventions, strengthened governmental regulations concerning public health, the utilization of combined treatment modalities, and concerted efforts focused on achieving health equity, with key developments shaping this period being the adoption of tailored treatment regimens, the integration of digital health technologies, the application of artificial intelligence in tracking disease progression, and localized efforts aimed at the near-eradication of Hepatitis C.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Which Key Market Drivers Powering Viral Hepatitis Market Expansion and Growth?
The escalating incidence of hepatitis is anticipated to fuel the expansion of the viral hepatitis market moving ahead. This infection, stemming from various viral and non-viral agents impacting the liver, leads to numerous health complications, principally involving inflammation and subsequent damage due to viral strains like Hepatitis A, B, C, D, and E. Indicatively, data released in April 2024 by the European Centre for Disease Prevention and Control, a governmental health body situated in Sweden, showed a notable surge in Hepatitis B virus (HBV) infections across 30 EU/EEA Member States; in 2022, a total of 28,855 cases were documented, marking a significant 78 percent rise from the 16,187 cases recorded the previous year in 2021. Furthermore, these 28,420 cases from 2022 correspond to an unadjusted incidence rate of 8.5 ailments per every 100,000 residents, thus confirming that the growing prevalence of hepatitis is expected to be a primary catalyst for the market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Viral Hepatitis Market?
To maintain their competitive edge within the viral hepatitis sector, the involved corporations are dedicated to making progress in both the creation and refinement of novel therapeutic agents. This constant pursuit of drug innovation significantly enhances the scientific comprehension of disease processes, thereby expediting the introduction of subsequent therapeutic options. Illustrating this, in November of 2022, the US biopharmaceutical entity, Gilead Sciences Inc., publicized that America's Food and Drug Administration (FDA) had consented to their supplemental new medicine application (sNDA) covering the 25 mg dosage of Vemlidy (tenofovir alafenamide) tablets, now authorized for once-daily administration against chronic hepatitis B virus (HBV) infection in pediatric individuals aged 12 and above who suffer from compensated liver conditions; this regulatory clearance was underpinned by the promising outcomes observed over 24 weeks in a Phase 2 clinical investigation involving this specific younger patient cohort.

What Are the Emerging Segments in the Viral Hepatitis Market?
The viral hepatitismarket covered in this report is segmented -

1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:
1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D; Hepatitis E

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

Who Are the Global Leaders in the Viral Hepatitis Market?
Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

Which are the Top Profitable Regional Markets for the Viral Hepatitis Industry?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.